Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines

Mass vaccination with a safe and effective vaccine may be the best way to control the COVID-19 pandemic. Heterologous prime-boost vaccination with the CoronaVac and AZD1222 vaccines may increase the immunogenicity elicited by either vaccine alone. This study sought to compare the immunogenicity of a...

Full description

Bibliographic Details
Main Authors: Guy Cohen, Pawornrath Jungsomsri, Jirath Sangwongwanich, Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda
Format: Article
Language:English
Published: Taylor & Francis Group 2022-11-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
heterologous prime-boost
vaccine combination
chadox1 ncov-19
azd1222
coronavac
immunogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2022.2052525

Internet

http://dx.doi.org/10.1080/21645515.2022.2052525

Similar Items